Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [(18)F]FDG PET/CT and [(18)F]FDG PET/MRI

利用[(18)F]FDG PET/CT和[(18)F]FDG PET/MRI评估免疫功能低下患者实体器官移植后疑似恶性肿瘤或感染。

阅读:1

Abstract

PURPOSE: To study the value of 2-deoxy-2-[(18)F]fluoro-D-glucose([(18)F]FDG) positron emission tomography/computed tomography (PET/CT) and [(18)F]FDG positron emission tomography/magnetic resonance imaging (PET/MRI) in assessing immunocompromised patients with suspected malignancy or infection. METHODS: [(18)F]FDG-PET/CT and [(18)F]FDG-PET/MRI examinations of patients who were immunocompromised after receiving lung, heart, pancreas, kidney, liver, or combined kidney-liver transplants were analyzed in this retrospective study. Patients underwent whole-body hybrid-imaging because of clinical signs of malignancy and/or infection. Findings were assessed by molecular features ([(18)F]FDG-uptake) and morphological changes. The final diagnosis, which was arrived at after review of clinical, laboratory, and histopathologic analyses and follow-up imaging studies, served as the reference standard. RESULTS: Altogether, (i) 28 contrast-enhanced [(18)F]FDG-PET/CT scans (CE-PET/CT), (ii) 33 non-contrast [(18)F]FDG-PET/CT scans (NC-PET/CT), and (iii) 18 [(18)F]FDG-PET/MRI scans were included. Additionally, 12/62 patients underwent follow-up PET imaging to rule out vital tumor or metabolic active inflammatory processes. CE-PET/CT exhibited 94.4% sensitivity, 80.0% specificity, 89.5% positive predictive value (PPV), 88.9% negative predictive value (NPV), and 89.3% accuracy with regard to the reference standard. NC-PET/CT exhibited 91.3% sensitivity, 80.0% specificity, 91.3% PPV, 80.0% NPV, and 87.9% accuracy. PET/MRI exhibited 88.6% sensitivity, 99.2% specificity, 99.6% PPV, 81.3% NPV, and 94.4% accuracy. Exact McNemar statistical test (one-sided) showed significant difference between the CT-/MR-component alone and the integrated PET/CT and PET/MRI for diagnosis of malignancy or infection (p value < 0.001). Radiation exposure was 4- to 7-fold higher with PET/CT than with PET/MRI. CONCLUSION: For immunocompromised patients with clinically unresolved symptoms, to rule out vital tumor manifestations or metabolic active inflammation, [(18)F]FDG-PET/MRI, CE-[(18)F]FDG-PET/CT, and NC-[(18)F]FDG-PET/CT exhibit excellent performance in diagnosing malignancy or infection. The main strength of PET/MRI is its considerably lower level of radiation exposure than that associated with PET/CT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。